Background {#s1}
==========

Juvenile idiopathic arthritis is a group of diseases characterized by arthritis of unknown origin, which is seen before age of 16 years \[[@R01]\]. It is a group of diseases that encompasses all forms of arthritis beginning before the age of 16 years and stays for more than 6 weeks. 250,000 children in the United States alone are estimated to be affected by Juvenile Idiopathic Arthritis (JIA). Short and long term disabilities are also caused by JIA. There are three major types of presentation of the term JIA, which encompasses a heterogeneous group of diseases: (a) oligo-arthritis, (b) polyarthritis and (c) systemic-onset JIA (SoJIA) \[[@R02]\]. One subspace, systemic JIA (sJIA), is the additional presence of exhausting fever, serositis (inflammation of the serous tissues of the body), fugitive rash, lymph adenopathy (disease of the lymph nodes, in which they are abnormal in size) and hepatosplenomegaly (a disorder where both the liver and spleen swell beyond their normal size). Osteoporosis, growth retardation, systemic amyloidosis and macrophage activation syndrome are some severe complications. These are observed more frequently in patients with the longstanding disease than in other JIA subclasses. Patients of sJIA have a range of other prominent features, which includes marked elevation of erythrocyte sedimentation rate (ESR) and C-reactive complement protein (CRP), leucocytes with high neutrophil counts and thrombocytosis. It has a yearly occurence of 2-20 cases per 100,000 population in countries having a high income.

IL-6 has a pleiotropic effect on inflammation, immune response, and hematopoiesis. It is a soluble mediator. Human IL-6 is composed of 212 amino acids, including a 28-amino-acid signal peptide. Its gene has been mapped to chromosome 7p21. Although the core protein is about 20kDa, glycosylation accounts for the size of 21-26 kDa of natural IL-6. Disproportioned continual synthesis of IL-6 has a pathological impact on chronic inflammation and autoimmunity. A humanized anti-IL-6 receptor Tocilizumab is an antibody was developed for the same reason \[[@R03]\]. It is evident that the production of IL-6 is particularly high in sJIA. By a variant of the gene encoding IL-6 in a significant fraction of patients, it can be genetically determined. A significant increase in soluble IL-6 receptor (sIL-6R) concentrations, in addition to the increase in serum IL-6, has been determined in the JIA patients. Different levels of IL-6 correlate with the activity of disease, pattern of fever and platelet counts, which indicates an important role of IL-6 in the pathogenesis of sJIA. A humanized anti-human IL-6 receptor antibody MRA (Tocilizumab) of kappa-IgG1 subclass is developed collaboratively by Osaka University and Chugai Pharmaceutical Company Ltd (Japan). MRA is humanized as the complementary determining regions of a mouse anti-human IL-6 receptor monoclonal antibody are grafted onto human IgG1 by using recombinant DNA technology \[[@R03]\].

Methodology {#s2}
===========

Selection of inhibitors {#s2a}
-----------------------

For the determination of inhibitors in the present examination, the existing inhibitors of IL-6 against Juvenile Idiopathic Arthritis were chosen from various literature studies. The accessibility of preexisting inhibitors is 20, chosen to promote perceptions ([Table1](#T1){ref-type="table"}).

Protein and Ligand preparation: {#s2b}
-------------------------------

The crystal structure of target protein, extracellular domain of IL-6 was retrieved from Protein Data Bank (PDB) with PDB ID: 1N26 \[[@R06]\] and was carried further for more studies of docking process ([Figure 1](#F1){ref-type="fig"}). The inhibitors accomplishing a PubChem CID have redeemed the 3D conformer of inhibitors and saved in SDF format \[[@R07]-[@R11]\]. Further, preparation of ligands was preceded by taking the 3D structure of all those compounds inserted in LegPrep module of Schrodinger suite, 2013 (Schrodinger. LLC, New York, NY) and were optimized through OPLS 2005 force field algorithm \[[@R13]-[@R18]\]. The prepared ligands were saved in a single SDF file for further docking studies \[[@R19]-[@R23]\].

The crystal structure of target protein, additional extracellular province of IL-6 was recovered from Protein Data Bank (PDB) with PDB ID: 1N26 and was sent for additional investigations of the docking process. The inhibitors achieving a PubChem ID redeemed the 3D conformer of inhibitors and spared as SDF design. Certain compounds lacked PubChem CID and 3D structures. Marvin Sketch was used to make the 3D structures of such compound and was allowed in SDF design \[[@R24]-[@R27]\]. Assist readiness of ligand was done before taking the 3D structure of each one of those compounds installed in LigPrep module of Schrodinger suite, 2013 (Schrodinger. LLC, New York, NY) and were advanced through OPLS 2005 power field calculation \[[@R28]-[@R32]\]. The ligands, which were ready, spared in single SDF petition for additionally docking investigations.

Molecular docking: {#s2c}
------------------

Molegro Virtual Docker (MVD) was used for the molecular docking studies, which was unified with high potential Piece-Wise Linear Potential (PLP) and MolDock scoring function \[[@R33]-[@R36]\]. All the preprepared 20 ligands were saved in one single SDF file. The PDB file of target protein consist pre-existing ligands, which were removed and prepared by detecting cavities, and those which were found in the first cavity, bear the highest volume were targeted for the further procedure of docking with ligands. Docking process possessing parameter of maximum reiteration of 1500, maximum population size 50, Grid solution 0.2 having a binding affinity, the protein and ligands were evaluated on the following confirmation of the Internal Electrostatic interaction (Internal ES), sp2-sp2 torsions and internal hydrogen bond interaction. The binding site is defined as the first cavity possessing high volume. A post dock study involves energy minimization and H-bond optimization. Setting of Simplex Evolution at max steps 300 and neighbor distance faster 1.00 \[[@R37]-[@R39]\]. After docking, to minimize the complex energy of ligand-receptor interaction the Nelder Mead Simplex Minimization (using non-grid force field and H-bond directionality) was used \[[@R40]-[@R42]\].

Virtual screening: {#s2d}
------------------

Using Methotrexate as a query compound, the present investigations were performed for the structure similarity search analysis from the PubChem database, which is maintained by NLM (National Library of Medicine, NCBI, NIH). The filtration properties parameter is set by the component rule of Lipinski\'s rule of five at Threshold \>=95% against NCBI\'s PubChem database \[[@R43]-[@R45]\].

Drug-Drug comparative study: {#s2e}
----------------------------

The unnamed complex structure was redeemed from an established drug docking result and was simply imported. It was cleaned by removing all ligand constraints and eventually imported the bestposed drug and exported as best drug docked file in SDF format. Again the complex structure was retrieved from virtual docking result and the procedure was repeated. The excel sheet was prepared to check all the affinities, hydrogen interaction and high re-rank score. An excel sheet was prepared in order to identify the best drug \[[@R46]-[@R47]\].

Pharmacophore studies: {#s2f}
----------------------

Pharmacophore studies involve different types of interactions between ligands and receptors. It includes H-bond interactions, electrostatic interactions, hydrophobic interactions, and aromatic interactions. The study is done using Accelrys Discovery Studio 3.5 DS Visualizer \[[@R46]-[@R48]\].

ADMET studies: {#s2g}
--------------

Owing to the superior affinity of best docked established compound Methotrexate (CID: 126941) and virtual screened compound PubChem CID-122677576, the bioactivity properties, and toxicity was predicted by using admetSAR \[[@R07]-[@R09]\].

Software, Suites and Web servers Used: {#s2h}
--------------------------------------

NCBI\'s PubChem was used to retrieve all the chemical 3D structures in SDF format. The ligands were optimized by using the software Schrodinger suite 2013 (Schrodinger.LLC, 2009, New York, NY). Flexible Docking was performed by making target and all the compounds in Molegro Virtual Docker 2010.4.0.0. Molecular Visualization was done with Accelrys Discovery Studio® Visualizer 3.5.0.12158 (Copyright© 2005-12, Accelrys Software Inc.). ADMET profiles were studied and calculated using admetSAR (Laboratory of Molecular Modelling and Design © 2012 East China University of Science and Technology, Shanghai Key Laboratory for New Drug-Drug Design).

Results and Discussion {#s3}
======================

The docking studies of complete pre-established 20 drugs were performed and it was found that the compound Methotrexate (CID: 126941) is the best-established compound. Table 2 as the compound having lowest energy with -105.677 as re-rank score shows the higher affinity score directed towards our target protein and has the great affinity properties like molecular weight 454.447 g/mol, 5 hydrogen bond donor and 12 hydrogen bond acceptor, topological polar surface area 211 A\^2 and log value of-1.8.Thus, the compound reveals the superior inhibitory affinity over protein IL-6.The docking studies were resulted in [Table 2](#T2){ref-type="table"}.

Further, the similarity search for this inhibitor displayed 269 compounds. [Table 3](#T3){ref-type="table"} contains the docking result of the top 10 of 269 virtual screened compounds. The compound with PubChem CID122677576 with higher affinity is selected. This compound has a molecular weight of 496.528 g/mol, 5 hydrogen bond donor and 12 hydrogen bond acceptor, a topological surface area of 208 A\^2and a log P value is -0.7. Similarly, among all 269virtual screened compounds and 20 pre-established compounds, the drug with PubChem CID: 122677576 have much potential inhibition against juvenile idiopathic arthritis over the target protein IL-6.

The compound with PubChem Id: 122677576 prove more efficient than the already established drug Methotrexate and it is shown in [Table 4](#T4){ref-type="table"}. External ligand interactions and Protein-ligand interactions, along with total energy evidently shows the stable interactions of the compound (PDB ID: 122677576) with the target protein IL-6. Moreover, steric energy for the established compound also indicates the better stability of the compound obtained after the virtual screening studies.

Pharmacophore study is done for the better clarification of the interactive attributes of the compound, which are important for the biological functioning of that compound. The pharmacophore mapping gives spatial essential systematic features of the molecular interaction with a specific target receptor apart from the method of molecular docking. Pharmacophore studies provide accurate query on the optimum interaction with suitable target annotations and represent the aligned poses of the molecule and help us to find the high interaction mode between target protein and compound. Owing to admirable affinity and good interaction profile of virtual screened compound (PubChemCID 122677576) over the most effective pre-established compound Methotrexate (PubChem CID 126941), the study carries forwarded to the pharmacophore results. Pharmacophore mapping results in the positive intensities of electrostatics as well as varying intensities and the charges in aromatic interaction, respectively. The pharmacophoric feature includes the study of different types of interactions, such as H-bond interactions, electrostatic interactions, hydrophobic interactions, aromatic interactions, and van der Waals (vdW) interactions. These interactions are shown below.

[Figure 2](#F2){ref-type="fig"} represents Van der Waals interaction between residues interactions of virtual screened compound (PubChem CID- 122677576) present in the cavity of IL-6 protein. The interaction in the figure represents the residues with ligands displayed in green to be van der Waals interaction and the residues displayed in pink to be electrostatic interactions. The figure depicts four hydrogen bond interaction; two with Ser72, one with Thr120 and Ser122 residues represented by a green dotted line. Consequently, the van der Waal interactions were also shown by the residues Thr124, Asp92, Leu90, Lys45, Val93, Phe155, Trp115 and Val175 were circled with green. Furthermore, the interaction of pi-pi between the Pro121 and the compound are depicted in orange color.

[Figure 3](#F3){ref-type="fig"} represents the receptor-ligand binding, by producing a signal by binding to a site on targeted IL-6 protein resulted in the change in conformation of IL-6 protein according to the ligand. In the figure receptor-ligand interaction of the most effective virtual screened compound (PubChem CID-122677576) with different amino acid residues present in the ligand. The figureshows the ligand-receptor interactions depicted by a black dotted line with residues Asp71, Ser72, Val91, Ser119, Pro121, Ser122, Thr124, Thr125, Thr120, Pro117 and His70. This interaction shows the high affinity of the virtual screened compound in comparison with best pre-established compound Methotrexate (PubCID-126941) having the lowest re-rank score.

ADMET profile: {#s3a}
==============

[Table 5](#T5){ref-type="table"} is the ADMET prediction of both the best-docked compound Methotrexate (PubChem CID 126941) and the best virtual screened compound (PubChem CID - 122677576). According to the table, brain penetration prediction i.e.Blood-Brain Barrier (BBB), Methotrexate and virtual screened compound (PubChem CID 122677576) are showing the negative value to the property of absorbing. Human Intestinal Absorption (HIA) shows the greater absorption in the intestine and both the compounds denote equal parameter. For the predictions of P-glycoprotein substrate and Pglycoprotein inhibitor, both the compounds show alternative similarity. At the absorption site of the P-glycoprotein Substrate, both the compounds show exactly the same probability while Pglycoprotein Inhibitor shows the values with high probability. In addition to the distribution of sub-cellular localization, both the compounds are localized in the mitochondria. The mitochondrial distribution of both compounds shows a distribution that is almost the same to each other. In case of metabolism, both the compounds are acting as the substrates as well as the inhibitors. The compounds display equivalent high inhibitory effect towards the target protein. The further study of bioactivity in the profile of excretion and toxicity is almost equivalent. In reference to carcinogens, they both show the same carcinogenicity. The mutagenicity of the compound can be predicted by ADMET regression toxicity study. Both the compounds in the properties of Rat Acute Toxicity are nearly equal to each other. The possibility of having higher toxicity than these two molecules is shown in [Table 6](#T6){ref-type="table"}. Further, the study of bioactivity in the profile of excretion and toxicity is similar.

Comparative ADMET profile study of the compounds and the control: {#s3b}
=================================================================

The comparative ADMET profile for the inhibitors was predicted based on the parameters such as Blood-Brain Barrier (BBB), Human Intestinal Absorption (HIA), AMES Toxicity and LD50. The established compound Methotrexate with PubChem CID:126941 and the best virtual screened compound with PubChem CID- 122677576 along with other top 2 compounds Salsalate having PubChemCID5161 and the compound having PubChemCID102026478 was preferred for comparative ADMET studies. These four compounds were graphically estimated using R-programming as shown in [Figure 4](#F4){ref-type="fig"}. The parameters: BBB, HIA, AMES toxicity and LD50 procured from the admetSAR database. The compounds were tabulated according to their predicted values and properties. So, according to the graph as well as [Table 7](#T7){ref-type="table"} among all the four compounds the values of BBB are similar in both the compound Methotrexate (PubChem CID 126941) and the compound (PubChem ID-102026478). Human Intestinal Absorption (HIA) value is similar in both the compound Methotrexate (PubChem CID 126941) and the compound (PubChem ID- 102026478). LD50 in rat is lower in Salsalate (PubChem ID-5161). The compound with PubChem ID-122677576 has higher HIA. Methotrexate has an equivalent property in LD50 in rat and Ames toxicity in comparison with compound (PubChem Id - 102026478), which also shows the regression in toxicity.

Conclusion {#s4}
==========

Inhibition of IL-6 interactions has now surfaced as an important drug target against Juvenile Idiopathic Arthritis. We study 20 preestablished inhibitors of IL-6 which are associated with JIA using molecular docking analysis, an inhibitor of IL-6 for JIA among presently effective inhibitor Methotrexate and virtual screened compound Pub CID: 122677576. We foresee Methotrexate and CID: 122677576 are structurally cognant. However, Methotrexate is a good inhibitor, but compound 122677576 has the lowest re-rank score and can emerge as an important drug in the treatment of disease in the future ahead.
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###### List of Established inhibitors collected from various literature

  S. No.   Inhibitors                  Pub ID     MW in gm/mol             HBD   HBA   Logp   Ref
  -------- --------------------------- ---------- -------------- --------- ----- ----- ------ ------------
  1        Cyclosporine A              5284373    1202.635                 5     12    7.5    \[[@R04]\]
  2        Chloroxine                  2722       214.045                  1     2     3.5    \[[@R05]\]
  3        Salazosulfapyridine         5359476    398.393                  3     9     2.3    \[[@R05]\]
  4        Methotrexate (MTX)          126941     454.447                  5     12    -1.8   \[[@R05]\]
  5        Aspirin                     2244       180.159                  1     4     1.2    \[[@R05]\]
  6        celecoxib (Celebrex)        2662       381.373                  1     7     3.4    \[[@R05]\]
  7        Diclofenac                  3033       296.147                  2     3     4.4    \[[@R05]\]
  8        Diflunisal (Dolobid)        3059       250.201                  2     5     4.4    \[[@R05]\]
  9        etodolac (Lodine)           3308       287.359                  2     3     2.8    \[[@R05]\]
  10       ibuprofen (Motrin, Advil)   3672       206.285                  1     2     3.5    \[[@R05]\]
  11       indomethacin (Indocin)      3715       357.79                   1     4     4.3    \[[@R05]\]
  12       Ketoprofen                  3825                      254.285   1     3     3.1    \[[@R05]\]
  13       Ketorolac                   3826       255.273                  1     3     1.9    \[[@R05]\]
  14       nabumetone (Relafen)        4409       228.291                  0     2     3.1    \[[@R05]\]
  15       Naproxen                    156391                    230.263   1     3     3.3    \[[@R05]\]
  16       oxaprozin (Daypro)          4614       293.322                  1     4     4.2    \[[@R05]\]
  17       piroxicam (Feldene)         54676228   331.346                  2     6     3.1    \[[@R05]\]
  18       Salsalate                   5161       258.229                  2     5     3      \[[@R05]\]
  19       sulindac (Clinoril)         1548887    356.411                  1     5     3.4    \[[@R05]\]
  20       tolmetin (Tolectin)         5509       257.289                  1     3     2.8    \[[@R05]\]

###### Docking results of Established Drugs

  LIGAND   FILE NAME      MOLDOCK SCORE   RERANK SCORE   H BOND
  -------- -------------- --------------- -------------- ----------
  126941   \[00\]126941   -165.255        -105.677       -10.8923
  126941   \[03\]126941   -129.781        -97.6819       -2.7623
  5161     \[01\]5161     -114.55         -90.8458       -6.49702
  4614     \[02\]4614     -119.216        -89.5275       -1.02526
  5161     \[02\]5161     -111.018        -88.7829       -3.65241
  3715     \[00\]3715     -118.311        -88.6118       -5
  4614     \[00\]4614     -123.091        -87.9868       -4.39387
  2244     \[01\]2244     -98.6621        -87.9747       -4.68577
  156391   \[00\]156391   -105.996        -87.7415       -4.97939
  3308     \[00\]3308     -115.385        -87.5747       -5.3458
  2662     \[00\]2662     -124.171        -87.5568       -1.91396

###### Virtual Screening results

  FILE NAME         MOLDOCK SCORE   RERANK SCORE   H BOND     MW
  ----------------- --------------- -------------- ---------- ---------
  \[00\]122677576   -191.912        -140.262       -5.94855   496.519
  \[00\]102026478   -217.813        -138.97        -11.4481   841.781
  \[00\]132255100   -181.506        -135.599       -5.68666   439.428
  \[00\]16218627    -180.136        -135.525       -7.672     440.413
  \[00\]100968121   -192.426        -135.379       -2.42808   610.661
  \[00\]128780      -173.361        -134.132       -6.10786   458.403
  \[00\]10696709    -178.155        -133.094       -2.54635   500.483
  \[00\]456144      -192.12         -132.787       -9.20054   712.667
  \[00\]444319      -178.728        -131.774       -7.70866   455.447
  \[01\]101755837   -199.698        -130.665       -6.95592   711.682

###### Drug-drug comparison

  Established Drug: Methotrexate       Virtual Screened Drug (PubChem id: 122677576)                         
  ------------------------------------ ----------------------------------------------- ---------- ---------- ----------
  Total Energy                         -173.204                                        -111.978   -195.561   -143.154
  External Ligand interactions         -185.718                                        -132.69    -209.335   -172.055
  Protein - Ligand interactions        -185.718                                        -132.69    -209.335   -172.055
  Steric (by PLP)                      -166.874                                        -114.476   -199.728   -137.014
  Steric (by LJ12-6)                                                                   -3.29                 -27.433
  Hydrogen bonds                       -18.843                                         -14.924    -9.606     -7.608
  Hydrogen bonds (no directionality)                                                   0                     0
  Electrostatic (short range)          0                                               0          0          0
  Electrostatic (long range)           0                                               0          0          0
  Cofactor -- Ligand                   0                                               0          0          0
  Steric (by PLP)                      0                                                          0          
  Steric (by LJ12-6)                                                                   0                     0
  Hydrogen bonds                       0                                               0          0          0
  Electrostatic                        0                                               0          0          0
  Water - Ligand interactions          0                                               0          0          0
  Internal Ligand interactions         12.513                                          20.712     13.774     28.9
  Torsional strain                     6.417                                           6.019      14.433     13.538
  Torsional strain (sp2-sp2)                                                           1.133                 1.451
  Hydrogen bonds                                                                       0                     0
  Steric (by PLP)                      11.605                                          1.996      7.111      1.223
  Steric (by LJ12-6)                                                                   11.565                12.688
  Electrostatic                        0                                               0          0          0
  Soft Constraint Penalty              0                                                          0          
  Search Space Penalty                 0                                                          0          

###### ADMET profile calculation of both best-docked compounds by AdmetSAR

  Virtual Screened Drug                         Established Drug                                                           
  --------------------------------------------- -------------------------------- -------- -------------------------------- --------
  Blood-Brain Barrier                           BBB-                             0.6563   BBB-                             0.9467
  Human Intestinal Absorption                   HIA+                             0.9575   HIA+                             0.8261
  Caco-2 Permeability                           Caco2-                           0.7248   Caco2-                           0.7754
  P-glycoprotein Substrate                      Substrate                        0.7871   Substrate                        0.8172
  P-glycoprotein Inhibitor                      Non-inhibitor                    0.6111   Non-inhibitor                    0.7752
                                                Non-inhibitor                    0.7509   Non-inhibitor                    0.9879
  Renal Organic Cation Transporter              Non-inhibitor                    0.8994   Non-inhibitor                    0.8886
  Distribution                                                                                                             
  Subcellular localization                      Mitochondria                     0.5355   Mitochondria                     0.4349
  Metabolism                                                                                                               
  CYP450 2C9 Substrate                          Non-substrate                    0.8783   Non-substrate                    0.85
  CYP450 2D6 Substrate                          Non-substrate                    0.7845   Non-substrate                    0.7968
  CYP450 3A4 Substrate                          Substrate                        0.584    Substrate                        0.5177
  CYP450 1A2 Inhibitor                          Non-inhibitor                    0.7249   Non-inhibitor                    0.9045
  CYP450 2C9 Inhibitor                          Non-inhibitor                    0.7417   Non-inhibitor                    0.907
  CYP450 2D6 Inhibitor                          Non-inhibitor                    0.9051   Non-inhibitor                    0.9231
  CYP450 2C19 Inhibitor                         Non-inhibitor                    0.693    Non-inhibitor                    0.9025
  CYP450 3A4 Inhibitor                          Non-inhibitor                    0.6359   Non-inhibitor                    0.8333
  CYP Inhibitory Promiscuity                    Low CYP Inhibitory Promiscuity   0.7285   Low CYP Inhibitory Promiscuity   0.9739
  Excretion                                                                                                                
  Toxicity                                                                                                                 
  Human Ether-a-go-go-Related Gene Inhibition   Weak inhibitor                   0.989    Weak inhibitor                   0.9564
                                                Non-inhibitor                    0.6529   Non-inhibitor                    0.6958
  AMES Toxicity                                 Non AMES toxic                   0.7703   Non AMES toxic                   0.9132
  Carcinogens                                   Non-carcinogens                  0.9039   Non-carcinogens                  0.9517
  Fish Toxicity                                 Low FHMT                         0.9896   Low FHMT                         0.9534
  Tetrahymena Pyriformis Toxicity               High TPT                         0.9052   High TPT                         0.7836
  Honey Bee Toxicity                            Low HBT                          0.7618   Low HBT                          0.8736
  Biodegradation                                Not ready biodegradable          0.989    Not ready biodegradable          0.9741
  Acute Oral Toxicity                           III                              0.5639   II                               0.731
  Carcinogenicity (Three-class)                 Non-required                     0.6139   Non-required                     0.6979

###### ADMET profile (Regression)

  Virtual Screened Drug: CID122677576   Established Drug                            
  ------------------------------------- ------------------ -------------- --------- --------------
  Aqueous solubility                    -3.643             LogS           -3.0651   LogS
  Caco-2 Permeability                   0.0081             LogPapp,cm/s   -0.3591   LogPapp,cm/s
  Distribution                                                                      
  Metabolism                                                                        
  Excretion                                                                         
  Toxicity                                                                          
  Rat Acute Toxicity                    2.6698             LD50,mol/kg    3.4955    LD50,mol/kg
  Fish Toxicity                         1.6179             pLC50,mg/L     1.82      pLC50,mg/L
  Tetrahymena Pyriformis Toxicity       0.3464             pIGC50,ug/L    0.2833    pIGC50,ug/L

###### Comparative ADMET profile of the test ligands and the control

  Compounds                   Blood-Brain Barrier (BBB+/BBB-)   Human Intestinal Absorption(HIA)   AMES toxicity             Carcinogenicity     LD50 in rat
  --------------------------- --------------------------------- ---------------------------------- ------------------------- ------------------- -------------
  CID 126941 (Methotrexate)   0.9467 (BBB-)                     0.8261 (HIA+)                      0.9132 (Non AMES Toxic)   Non- carcinogenic   3.4955
  CID 5161 (Salsalate)        0.8946 (BBB+)                     0.9161 (HIA+)                      0.9731 (Non AMES Toxic)   Non- carcinogenic   2.4607
  CID (122677576)             0.6563 (BBB-)                     0.9575 (HIA+)                      0.7703 (Non AMES Toxic)   Non- carcinogenic   2.6698
  CID (102026478)             0.9467 (BBB-)                     0.8261 (HIA+)                      0.9132 (Non AMES Toxic)   Non- carcinogenic   3.4955

![Protein 3D structure of IL-6 obtained from PDB (PDBID: 1N26) Visualization in Accelrys Discovery Studio](97320630015121F1){#F1}

![The most effective compound (PubChem id: 122677576) binding with IL-6 obtained from the virtual screening studies shows Van der Waals Interaction](97320630015121F2){#F2}

![The most effective compound (PubChem id: 122677576) binding with IL-6 obtained from the virtual screening studies shows Ligand-receptor Interaction](97320630015121F3){#F3}
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